Shanghai Competitors

S1R Stock

EUR 1.58 0.01 0.63%

Shanghai Pharmaceuticals competes with AmerisourceBergen, Cardinal Health, Henry Schein, Sinopharm Group, and SINOPHARM GROUP; as well as few others. The company classifies itself under Healthcare sector and is part of Medical Distribution industry. Analyzing Shanghai Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Shanghai Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Shanghai Pharmaceuticals Correlation with its peers.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Shanghai Pharmaceuticals competition on your existing holdings.

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
0.08	1.58	4.89

Details

Intrinsic

Valuation

Low	Real	High
0.08	1.70	5.01

Details

Shanghai Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Shanghai Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Shanghai and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Shanghai Pharmaceuticals does not affect the price movement of the other competitor.

	ABG	CLH	HS2	S1R	X2S	X2S1	PBV	59Z	PD2
ABG		0.92	0.65	0.57	0.4	0.4	0.88	-0.48	0.18	ABG
CLH	0.92		0.68	0.71	0.55	0.56	0.92	-0.44	0.33	CLH
HS2	0.65	0.68		0.64	0.5	0.51	0.77	-0.22	0.52	HS2
S1R	0.57	0.71	0.64		0.93	0.94	0.66	-0.3	0.51	S1R
X2S	0.4	0.55	0.5	0.93		0.99	0.5	-0.23	0.49	X2S
X2S1	0.4	0.56	0.51	0.94	0.99		0.5	-0.22	0.48	X2S1
PBV	0.88	0.92	0.77	0.66	0.5	0.5		-0.46	0.51	PBV
59Z	-0.48	-0.44	-0.22	-0.3	-0.23	-0.22	-0.46		-0.37	59Z
PD2	0.18	0.33	0.52	0.51	0.49	0.48	0.51	-0.37		PD2
	ABG	CLH	HS2	S1R	X2S	X2S1	PBV	59Z	PD2

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

High positive correlations

X2S1	+ 0.99	X2S
X2S1	+ 0.94	S1R
X2S	+ 0.93	S1R
CLH	+ 0.92	ABG
PBV	+ 0.92	CLH
PBV	+ 0.88	ABG

High negative correlations

59Z	- 0.48	ABG
59Z	- 0.46	PBV
59Z	- 0.44	CLH
PD2	- 0.37	59Z
59Z	- 0.3	S1R
59Z	- 0.23	X2S

Risk-Adjusted Indicators

There is a big difference between Shanghai Stock performing well and Shanghai Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Shanghai Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
ABG	0.94	0.09	0.08	0.15	1.02	(1.12)	2.65	(2.10)	6.48
CLH	1.25	0.20	0.12	0.58	1.32	(1.50)	3.25	(2.57)	12.11
HS2	1.44	0.02	0.01	0.06	1.72	(1.49)	3.33	(2.79)	10.06
S1R	2.39	0.55	0.16	0.60	2.63	(3.21)	5.80	(4.35)	21.18
X2S	1.94	0.47	0.16	0.67	2.27	(2.32)	4.47	(3.20)	18.93
X2S1	2.11	0.48	0.17	0.65	2.30	(2.62)	4.65	(3.23)	17.46
PBV	1.23	0.18	0.12	0.21	1.10	(1.71)	2.58	(1.96)	10.42
59Z	1.08	(0.12)	0.00	(0.26)	0.00	0.00	2.04	(2.03)	6.30
PD2	1.98	0.74	0.32	(3.67)	1.37	(2.73)	4.08	(2.55)	35.22

Unable to evaluate fundamental data of [ABG.F, CLH.F, HS2.F, S1R.F, X2S.F, X2S1.F, PBV.F, 59Z.F, PD2.F] at this time. Please try again later

All Fundamental Data

Shanghai Pharmaceuticals Competitive Analysis

The better you understand Shanghai Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Shanghai Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Shanghai Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	S1R	ABG	CLH	HS2	X2S	X2S1	PBV	59Z	PD2
	0.63 1.58 Shanghai	0.37 215.70 AmerisourceBergen	0.94 112.20 Cardinal	2.60 66.06 Henry	1.54 2.64 Sinopharm	1.55 13.10 SINOPHARM	0.67 75.50 Prestige	0.70 14.40 MEDIPAL	1.34 29.40 Patterson
Market Volatility (90 Days Market Risk)	Very risky	Very steady	Very steady	Very steady	Relatively risky	Not too volatile	Very steady	Very steady	Not too volatile
Market Performance (90 Days Performance)	Good	Modest	OK	Insignificant	Good	Good	Good	Very Weak	Good
Odds of Financial Distress (Probability Of Bankruptcy)	Low	Low	Below Average	Low	Low	Low	Low	Low	Low
Current Valuation (Equity Enterprise Value)	Under Valued	Fairly Valued	Under Valued	Fairly Valued	Under Valued	Under Valued	Under Valued	Fairly Valued	Over Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Trade Advice (90 Days Macroaxis Advice)	Strong Buy	Buy	Strong Buy	Strong Hold	Strong Buy	Strong Buy	Strong Buy	Hold	Strong Hold
Current Ratio	1.23	0.95	1.12	1.65	1.29	1.29	2.16	1.23	1.83
Net Asset	163.44 B	56.56 B	43.88 B	8.61 B	335.41 B	N/A	3.67 B	N/A	2.74 B
Profit Margin	0.0236	0.0072	-0.0066	0.0425	0.0145	0.0145	0.19	0.0091	0.0313
EBITDA	10.73 B	3.09 B	72 M	977 M	20.76 B	23.5 B	358.84 M	60.12 B	368.53 M
Operating Margin	0.0351	0.0112	0.0082	0.0694	0.0394	0.0394	0.31	0.0138	0.0368
Current Valuation	8.94 B	33.88 B	20.94 B	11.9 B	15.96 B	N/A	4.2 B	N/A	3.23 B
Price To Book	0.67	5.05	15.45	3.09	0.89	N/A	1.87	N/A	2.72
Five Year Return	2.74	1.43	3.12	N/A	2.38	N/A	N/A	N/A	2.52
Beta	0.33	0.53	0.77	0.79	0.72	0.76	0.6	0.26	1.27
Number Of Employees	47.06 K	39 K	45.57 K	22 K	113.23 K	113.23 K	535	12.8 K	7.7 K
Shares Outstanding	919.07 M	202.26 M	257.64 M	131.28 M	1.34 B	624.13 M	49.69 M	209.96 M	97.07 M
Cash Flow From Operations	5.06 B	2.7 B	3.12 B	602 M	9.31 B	N/A	259.92 M	34.45 B	(980.99 M)
Annual Yield	0.0385	0.0123	0.0253	N/A	0.0457	0.0492	N/A	0.0273	0.0382
Total Debt	7.16 B	4.63 B	4.74 B	1.04 B	8.42 B	86.79 B	1.48 B	30.36 B	488.55 M
Return On Equity	0.1	0.5	-1.71	0.12	0.13	0.13	0.13	0.0597	0.19
Z Score	1.6	7.6	5.8	6.4	1.0	N/A	0.6	N/A	5.0
Return On Asset	0.0281	0.0294	0.0223	0.0642	0.0364	0.0364	0.0576	0.0161	0.0508
Book Value Per Share	17.9	-0.88	-8.54	26.15	21.01	105.05	33.95	2636.24	10.73
Total Asset	163.44 B	56.56 B	43.88 B	8.61 B	335.41 B	N/A	3.67 B	N/A	2.74 B
Debt To Equity	0.67	152.8	3.74	41.5	0.93	0.93	163.1	0.047	50.8
Last Dividend Paid	0.42	1.87	1.98	N/A	0.75	0.75	N/A	23.0	1.04
Target Price	N/A	140.85	57.92	83.5	N/A	N/A	63.5	N/A	34.55
Shares Owned By Institutions	32.12	77.85	90.36	98.99	50.99	0.01	99.18	28.77	84.37
Market Capitalization	9.17 B	29.69 B	18.43 B	9.53 B	7.98 B	7.05 B	2.82 B	2.57 B	2.47 B
Price To Earning	6.59	17.93	10.35	16.81	6.1	7.03	21.3	17.52	18.07
Price To Earnings To Growth	2.42	1.55	0.64	1.92	50.46	N/A	1.71	N/A	2.06
Price To Sales	0.0384	0.13	0.11	0.84	0.0144	N/A	2.53	N/A	0.4
Net Income	5.09 B	1.7 B	(933 M)	538 M	7.76 B	7.87 B	205.38 M	26.47 B	203.21 M
Earnings Per Share	0.23	7.77	-4.3	3.51	0.35	1.77	3.86	0.89	1.91
Shares Owned By Insiders	22.0	16.95	0.39	1.01	0.01	N/A	0.82	9.02	10.62
Revenue	215.82 B	238.59 B	181.36 B	12.65 B	521.05 B	546.15 B	1.09 B	3.35 T	6.5 B
Cash And Equivalents	23.68 B	2.88 B	3.41 B	88.11 M	34.36 B	34.36 B	29.04 M	230.57 B	95.65 M
Cash Per Share	8.33	13.68	11.73	0.59	11.01	55.05	0.58	N/A	1.03
Gross Profit	28.41 B	8.33 B	6.54 B	3.83 B	44.05 B	44.05 B	627.87 M	217.44 B	1.29 B
Day Typical Price	1.58	215.7	112.2	66.06	2.64	13.1	75.5	14.4	29.4
Accumulation Distribution	0.0063	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Facilitation Index	0.01	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Daily Balance Of Power	(1.00)	(9,223,372,036,855)	9.2 T	(9,223,372,036,855)	9.2 T	9.2 T	9.2 T	9.2 T	(9,223,372,036,855)
Period Momentum Indicator	(0.01)	(0.80)	1.05	(1.76)	0.04	0.2	0.5	0.1	(0.40)
Rate Of Daily Change	0.99	1.0	1.01	0.97	1.02	1.02	1.01	1.01	0.99
Day Median Price	1.58	215.7	112.2	66.06	2.64	13.1	75.5	14.4	29.4
Price Action Indicator	N/A	(0.40)	0.52	(0.88)	0.02	0.1	0.25	0.05	(0.20)
Coefficient Of Variation	574.48	1062.1	846.1	3823.56	543.45	538.82	795.75	(1,326)	627.7
Mean Deviation	2.39	0.9406	1.25	1.44	1.94	2.11	1.23	1.08	1.98
Jensen Alpha	0.5457	0.0942	0.1996	0.0236	0.4698	0.482	0.175	(0.12)	0.7382
Total Risk Alpha	0.4738	0.0746	0.156	(0.01)	0.4105	0.4223	0.1497	(0.15)	0.603
Sortino Ratio	0.1612	0.0806	0.1189	0.0098	0.1571	0.1678	0.1199	N/A	0.3185
Downside Variance	11.4	1.2	2.43	3.12	8.71	8.08	2.09	N/A	4.99
Standard Deviation	3.31	1.28	1.84	1.89	2.7	2.74	1.64	1.36	4.67
Kurtosis	2.51	1.18	4.23	1.75	3.43	1.66	3.08	0.6874	43.41
Potential Upside	5.8	2.65	3.25	3.33	4.47	4.65	2.58	2.04	4.08
Treynor Ratio	0.6021	0.1511	0.5816	0.055	0.6685	0.6479	0.2115	(0.26)	(3.67)
Maximum Drawdown	21.18	6.48	12.11	10.06	18.93	17.46	10.42	6.3	35.22
Variance	10.97	1.64	3.39	3.58	7.26	7.53	2.67	1.85	21.8
Market Risk Adjusted Performance	0.6121	0.1611	0.5916	0.065	0.6785	0.6579	0.2215	(0.25)	(3.66)
Risk Adjusted Performance	0.1455	0.0784	0.0993	0.0265	0.1528	0.1541	0.1047	(0.06)	0.1345
Skewness	0.0158	0.5122	0.9769	0.6662	(0.36)	(0.15)	0.9577	0.6596	5.95
Semi Deviation	2.63	1.02	1.32	1.72	2.27	2.3	1.1	N/A	1.37
Information Ratio	0.1644	0.069	0.1007	0.0091	0.1721	0.1739	0.106	(0.1)	0.1524
Value At Risk	(4.35)	(2.10)	(2.57)	(2.79)	(3.20)	(3.23)	(1.96)	(2.03)	(2.55)
Expected Short fall	(3.21)	(1.12)	(1.50)	(1.49)	(2.32)	(2.62)	(1.71)	N/A	(2.73)
Downside Deviation	3.38	1.1	1.56	1.77	2.95	2.84	1.45	N/A	2.23
Semi Variance	6.9	1.04	1.75	2.97	5.15	5.28	1.22	N/A	1.87

Shanghai Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Shanghai Pharmaceuticals Competition

Shanghai Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Shanghai Pharmaceuticals in relation to its competition. Shanghai Pharmaceuticals' competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Shanghai Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Shanghai Pharmaceuticals' competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Shanghai Pharmaceuticals, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Shanghai Pharmaceuticals position

In addition to having Shanghai Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Marijuana Thematic Idea Now

Marijuana

Small and mid-cap equities that are involved in production and delivery of Marijuana products. This theme is designed for investors that are willing to accept higher levels of market risk inherited by Marijuana production in the United States. The Marijuana theme has 49 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marijuana Theme or any other thematic opportunities.

View All Next

Launch

Other Information on Investing in Shanghai Stock

Shanghai Pharmaceuticals financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Pharmaceuticals security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC